期刊
MOLECULES
卷 26, 期 7, 页码 -出版社
MDPI
DOI: 10.3390/molecules26071981
关键词
aurora kinase B (AURKB); cancer; AURKB regulation; AURKB inhibitors; therapy related drug resistance; combination therapy
资金
- Innovative Young Biotechnologist Award, Department of Biotechnology, Govt. of India [BT/09/IYBA/2015/10]
- Centre of Excellence grant, Department of Biotechnology, Govt. of India [BT/PR32404/MED/30/2136/2019]
- Hyderabad Eye Research Foundation, LV Prasad Eye Institute, India
AURKB plays a critical role in tumor development, therapy-related drug resistance, and its inhibition as a potential therapeutic strategy for cancer. Its dysregulation is associated with malignant growth of tumors.
Aurora kinase B (AURKB) is a mitotic serine/threonine protein kinase that belongs to the aurora kinase family along with aurora kinase A (AURKA) and aurora kinase C (AURKC). AURKB is a member of the chromosomal passenger protein complex and plays a role in cell cycle progression. Deregulation of AURKB is observed in several tumors and its overexpression is frequently linked to tumor cell invasion, metastasis and drug resistance. AURKB has emerged as an attractive drug target leading to the development of small molecule inhibitors. This review summarizes recent findings pertaining to the role of AURKB in tumor development, therapy related drug resistance, and its inhibition as a potential therapeutic strategy for cancer. We discuss AURKB inhibitors that are in preclinical and clinical development and combination studies of AURKB inhibition with other therapeutic strategies.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据